Literature DB >> 32038772

Inhibition of Dermatitis Development by Sopungsan in Nc/Nga Mice.

Yuba Raj Pokharel1, Sung Chul Lim2, Sang Chan Kim3, Hoo Kyun Choi1, Keon Wook Kang1.   

Abstract

Sopungsan (SS) is a traditional Korean decoction used for the treatment of dermatitis. The aim of this study is to confirm whether or not SS has a preventive effect on the development of atopic dermatitis in dinitrochlorobenzene-applied Nc/Nga mice. SS was administered orally to Nc/Nga mice, which led to the remarkable suppression of the development of dermatitis, as determined by a histological examination and the serum IgE levels. Moreover, SS inhibited the production of thymus- and activation-regulated chemokine (TARC) and its mRNA expression in a keratinocyte cell line, HaCaT, which had been stimulated with tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). Activation of the nuclear factor-κB (NF-κB) or activator protein-1 (AP-1) is one of key steps in the signaling pathways mediating induction of TARC. In this study, SS selectively suppressed NF-κB activation which may be essential for TARC expression in TNF-α/IFN-γ treated keratinocytes. The inhibitory effect of SS on NF-κB activation and TARC production might be associated with the anti-dermatitic effects of SS. © Korean Society of Toxicology 2008.

Entities:  

Keywords:  Anti-dermatitic activity; Atopic dermatitis; NF-κB; Sopungsan; TARC

Year:  2008        PMID: 32038772      PMCID: PMC7006310          DOI: 10.5487/TR.2008.24.1.017

Source DB:  PubMed          Journal:  Toxicol Res        ISSN: 1976-8257


  13 in total

1.  Morphology of atopic eczema.

Authors:  N A Soter
Journal:  Allergy       Date:  1989       Impact factor: 13.146

2.  Mechanism of thymus- and activation-regulated chemokine (TARC)/CCL17 production and its modulation by roxithromycin.

Authors:  Mayumi Komine; Takashi Kakinuma; Shinji Kagami; Yasushi Hanakawa; Koji Hashimoto; Kunihiko Tamaki
Journal:  J Invest Dermatol       Date:  2005-09       Impact factor: 8.551

3.  A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin.

Authors:  C Vestergaard; K Bang; B Gesser; H Yoneyama; K Matsushima; C G Larsen
Journal:  J Invest Dermatol       Date:  2000-10       Impact factor: 8.551

4.  Regulated production of the T helper 2-type T-cell chemoattractant TARC by human bronchial epithelial cells in vitro and in human lung xenografts.

Authors:  M C Berin; L Eckmann; D H Broide; M F Kagnoff
Journal:  Am J Respir Cell Mol Biol       Date:  2001-04       Impact factor: 6.914

5.  Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice.

Authors:  S Kawasaki; H Takizawa; H Yoneyama; T Nakayama; R Fujisawa; M Izumizaki; T Imai; O Yoshie; I Homma; K Yamamoto; K Matsushima
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

6.  The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4.

Authors:  T Imai; M Baba; M Nishimura; M Kakizaki; S Takagi; O Yoshie
Journal:  J Biol Chem       Date:  1997-06-06       Impact factor: 5.157

7.  Persimmon leaf extract and astragalin inhibit development of dermatitis and IgE elevation in NC/Nga mice.

Authors:  M Kotani; M Matsumoto; A Fujita; S Higa; W Wang; M Suemura; T Kishimoto; T Tanaka
Journal:  J Allergy Clin Immunol       Date:  2000-07       Impact factor: 10.793

Review 8.  Atopic dermatitis: immunobiology and treatment with immune modulators.

Authors:  D Y Leung
Journal:  Clin Exp Immunol       Date:  1997-01       Impact factor: 4.330

9.  Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice.

Authors:  H Matsuda; N Watanabe; G P Geba; J Sperl; M Tsudzuki; J Hiroi; M Matsumoto; H Ushio; S Saito; P W Askenase; C Ra
Journal:  Int Immunol       Date:  1997-03       Impact factor: 4.823

10.  Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis.

Authors:  Hirotoshi Furukawa; Masanobu Takahashi; Koichiro Nakamura; Fumio Kaneko
Journal:  J Dermatol Sci       Date:  2004-12       Impact factor: 4.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.